FILE 'HOME' ENTERED AT 14:20:55 ON 08 MAR 2006

=> file reg

=>

Uploading C:\Program Files\Stnexp\Queries\10531237.str

chain nodes : 25 26 27 28 ring nodes : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 chain bonds : 2-26 7-20 13-19 15-25 26-27 26-28 ring bonds : 1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10 11-12 11-16 12-13 14-15 15-16 17-18 17-21 17-24 18-19 19-20 20-21 21-22 22-23 23-24 exact/norm bonds : 17-18 17-21 17-24 18-19 19-20 20-21 21-22 22-23 23-24 26-27 exact bonds : 2-26 7-20 13-19 15-25 normalized bonds : 1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10 11-12 11-16 12-13 13-14 14-15 15-16 isolated ring systems : containing 1 : 11 : 17 :

### Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:CLASS 26:CLASS 27:CLASS 28:CLASS

### STRUCTURE UPLOADED

L1

=> d l1

L1 HAS NO ANSWERS

L1 STR

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

L3 1 SEA SSS FUL L1

=> file ca

=> s 13

L4 1 L3

=> d ibib abs fhitstr

L4 ANSMER 1 OF 1
ACCESSION NUMBER:

111:21527 CA

Preparation of quinolinyl pyrrolopyrazoles as

TOP-β signal transduction inhibitors

Beight, Dougles Made; Sawyer, Jason Scott; Yingling,
Jonathan Michael

Bil Lilly and Company, USA

SOURCE:

DOCUMENT TYPE:

PATENT ASSIGNEE(S):

PATENT APPI., 24 pp.

PATENT APPI., 24 pp. DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION: DATE APPLICATION NO. PATENT NO. KING DATE TG

CA 2501322 AA 20040610 CA 2003-2501322 20031110
AU 2003291643 A1 20040618 AU 2003-291643 20031110
BR 2003.015337 A 20050816 BR 2003-15337 20031110
EP 1565471 A1 20050824 EP 2003-758531 20031110
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LIT, LU, NL, SE, MC, PT, 1E, SI, LT, LV, PT, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
US 2006040983 A1 20060223 US 2005-531237 20050413
NO 2005003045 A 20050621 NO 2005-3045 20050613
PRIORITY APPLN. INFO.: US 2002-428893P P 20021122 WO 2003-US32747 W 20031110

ANSWER 1 OF 1 CA COPYRIGHT 2006 ACS on STN (Continued)

REPERENCE COUNT:

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

GI

ANSWER 1 OF 1 CA COPYRIGHT 2006 ACS on STN (Continued)

The title compds. I and II, useful in treating cancer in a patient, were prepared E.g., a multi-step synthesis of II, starting from 6-bromo-4-methylquinoline and Me 6-methylpyridine-2-carboxylate (prepns. given), was given. The compds. I and II inhibit the TGF-B type I receptor kinase domain with IC50 of <20 µM, while exhibiting less toxicity in vivo than structurally related compds. as disclosed in PCT/US02/11884. The pharmaceutical composition comprising the compound

PCT/US04/1100...

II is
 claimed.

IT 700874-72-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological atudy); PREP (Preparation); USES (Uses)
 (preparation of quinolinyl pyrrolopyrazoles as TGP-β signal

(Uses)
 (preparation of quinolinyl pyrrolopyrazoles as TGP-β signal
 transduction inhibitors)
700874-72-2 CA
6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4Hpyrrolo[1,2-b]pyrazol-3-yl]- (9CI) (CA INDEX NAME)

=> file marpat

=> s l1 full

FULL SEARCH INITIATED 14:21:44 FILE 'MARPAT'

FULL SCREEN SEARCH COMPLETED - 86 TO ITERATE

100.0% PROCESSED 86 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

L5 1 SEA SSS FUL L1

=> d ibib abs fqhit

```
L5 ANSWER 1 OF 1 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 138:4598 MARPAT
TITLE: Preparation of substituted
5,6-dihydro-4H-pyrrolo[1,2-
b]pyrazoles as TGF-B signal transduction inhibitors
INVENTOR(S): Sawyer, Jason Scott; Beight, Douglas Wada; Ciapetti, Paole; Decollo, Todd Vincent; Godfrey, Alexander Glenn; Goodson, Theodore, Jr.; Herron, David Kent;
                                                                                                                                                                                            Mong-yu; Liao, Junkai; Mcmillen, William Thomas; Miller, Shawn Christopher; Mort, Nicoles Anthony; Yingling, Jonethan Michael; Smith, Edward C. R. Bli Lilly and Company, USA; et al. PCT Int. Appl., 308 pp. CODEN: PIXXD2 Patent English 1
   PATENT ASSIGNEE(S):
SOURCE:
   DOCUMENT TYPE:
LANGUAGE:
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
                              PATENT NO. KIND DATE APPLICATION NO. DATE

MO 2002094833 A1 20021128 WO 2002-US11884 20020513

M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LK, LIS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RM: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BP, BJ, CP, CO, CI, CM, GA, GN, GQ, GM, ML, MR, NE, SN, TD, TQ

CA 2446820 A2 20021128 CA 2002-2446820 20020513

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NC, SE, MC, PT, IE, SI, LT, LV, PI, RO, MK, CY, AL, TR

BR 2002009919 A 20040330 CN 151157 A 20040330 CN 151157 A 20040330 CN 251157 A 20040330 CN 25125825 A 20051028 MC 2002-591506 20020513

NZ 528555 A 20051028 MZ 2002-591506 20020513

NZ 528555 A 20051028 MZ 2003-8546 20020513

NG 2001-2934644  20020031 CN 2003-6525 20020513

NG 2001-2934649 20010524 MC 2002-2934649 20010524

NG 2001-2934649 20010524 MC 2002-2931884 20020513
BR 2002009999
CN 1511157
JP 2004535404
NZ 528525
ZA 2003008546
US 2004106604
NO 2003005193
PRIORITY APPLN. INFO.:
 GI
```

L5 ANSWER 1 OF 1 MARPAT COPYRIGHT 2006 ACS on STN

= 346-4 348-2

H<sub>2</sub>C CH<sub>2</sub> G39

claim 1  $$\rm or\ N^{-}oxides$  and pharmaceutically acceptable salts, esters and prodrugs

THERE ARE 13 CITED REFERENCES AVAILABLE FOR REFERENCE COUNT:

RECORD. ALL CITATIONS AVAILABLE IN THE RE

L5 ANSWER 1 OF 1 MARPAT COPYRIGHT 2006 ACS on STN (Continued)

$$(R^3)_{p} \xrightarrow{N}_{N}^{N}_{N}$$

Title compds. I [R1 = Ph, pyridine, pyridine-N-oxide, quinoline, naphthyridine, etc.; R2 = quinoline, quinoline-N-oxide, naphthalene, pyridine, pyridine, pyridine, pyridine, pyridine, pyridine, pyridine, promote = 1.8; R2 = H, alkyl, alkylhydroxy, hydroxy, dialkylamino, etc.; X = C, O, S] were prepared


instance, 1-[[2-(6-Bromoquinolin-4-yl)-1-(pyridin-2-yl)ethylidene)amino)pyrrolidin-2-one (preparation given) was treated NaH in DMP at 80-85° for 18 h to afford II in 54% yield. Selected compds. of the invention had IC50 < 20.00  $\mu$ M for the TGP- $\beta$  type I receptor.


- 284

=> file reg

=>

Uploading C:\Program Files\Stnexp\Queries\237.str





11 20 21
ring nodes:
1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17 18 19
chain bonds:
2-20 7-15 11-14 20-21
ring bonds:
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10 12-13 12-16 12-19 13-14
14-15 15-16 16-17 17-18 18-19
exact/norm bonds:
11-14 12-13 12-16 12-19 13-14 14-15 15-16 16-17 17-18 18-19 20-21
exact bonds:
2-20 7-15
normalized bonds:
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10

Match level :

chain nodes :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:CLASS 21:CLASS

L6 STRUCTURE UPLOADED

isolated ring systems : containing 1 : 12 :

=> d 16 L6 HAS NO ANSWERS L6 STR

Structure attributes must be viewed using STN Express query preparation.

=> s 16 full L8 14 SEA SSS FUL L6

=> file ca

=> s 18 L9 2 L8

=> d ibib abs fhitstr 1-2

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: PATENT NO. KIND DATE APPLICATION NO. MO 2004048382 A1 20040610 MO 2003-U332747 20031110
W: A8, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DB, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IM, IS, JP, KE, KG, KP, KE, KZ, LC, LK, LK, LK, LT, LU, LV, MA, MD, MG, MK, NN, MN, MX, MZ, NI, MO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZM, BY, KG, KZ, MD, RU, ST, SL, SZ, TZ, UG, ZM, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, SF, IF, PR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BP, BJ, CP, CG, CI, CM, QA, GN, GQ, GM, ML, MR, NE, SN, TD,

TO CA 2501322 AA 20040610 CA 2003-2501322 20031110 AU 2003291643 A1 20040618 AU 2003-2501322 20031110 BR 2003015337 A 20050816 BR 2003-15337 20031110 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LIT, LU, NL, SE, MC, PT, IE, SI, LT, LV, PT, RO, MX, CY, AL, TR, BG, CZ, EE, HU, SK US 2006040983 A1 20060223 US 2005-531237 20050413 NO 2005-03045 A 20050621 NO 2005-03045 PRIORITY APPLN. INFO. : US 2002-428893P P 20021222

WO 2003-US32747 W 20031110

GI

ANSWER 1 OF 2 CA COPYRIGHT 2006 ACS on STN (Continued)

REFERENCE COUNT: THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

PORMAT

L9 ANSWER 1 OF 2 CA COPYRIGHT 2006 ACS on STN (Continued)

The title compds. I and II, useful in treating cancer in a patient, were prepared E.g., a multi-step synthesis of II, starting from 6-bromo-4-methylquinoline and Me 6-methylpyridine-2-carboxylate (prepns. given), was given. The compds. I and II inhibit the TGF-6 type I receptor kinase domain with ICSO of <30 µM, while exhibiting less toxicity in vivo than structurally related compds. as disclosed in PCT/USO2/11884. The pharmaceutical composition comprising the compound

claimed.
700874-72-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological atudy); PREP (Preparation); USES (Uses)

(Uses)
 (preparation of quinolinyl pyrrolopyrazoles as TGP-β signal
 transduction inhibitors)
700874-72-2 CA
6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4Hpyrrolo[1,2-b]pyrazol-3-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 2 OF 2 CA COPYRIGHT 2006 ACS ON STN ACCESSION NUMBER: 138:4598 CA TITLE: Preparation of substituted 5,6-dihydro-4H-pyrrolo[1,2-

2-bjpyrazoles as TGP-β signal transduction inhibitors Sawyer, Jason Scott; Beight, Douglas Wade; Ciapetti, Paole; Decollo, Todd Vincent; Godfrey, Alexander Glenn; Goodson, Theodore, Jr.; Herron, David Kent; INVENTOR (S):

Hong-yu; Liao, Junkai; Mcmillen, William Thomas; Miller. Shawn Christopher; Mort, Nicolas Anthony; Yingling, Jonathan Michael; Smith, Edward C. R. Eli Lilly and Company, USA; et al. PCT Int. Appl., 305 pp. CODEN: PIXXD2 Patent English

PATENT ASSIGNEE(S): SOURCE:

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

	PA'	FENT	NO.			KIN	D	DATE			APPI	LICAT	ION	NO.		D.	ATE	
							-									-		
	WO	2002	0948	33		A1		2002	1128		WO 2	2002 -	US11	884		2	0020	513
		W:	AR,	AG,	AL,	AM,	AT,	ΑU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
			co,	CR,	CU,	CZ,	DΕ,	DK,	DM,	DZ,	EÇ,	EE,	ES,	PI,	GB,	GD,	GE,	GH,
			GM,	HR,	ΗU,	ID,	IL,	IN,	IS,	J₽,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,
			LS,	LT,	LU.	LV,	MA,	MD,	MG,	MK,	MN.	MW.	MX,	MZ,	NO.	NZ,	OM,	PH.
			PL,	PT,	RO.	RU,	SD,	SE.	SG.	SI.	SK.	SL.	TJ.	TM.	TN.	TR.	TT.	TZ.
			UA,	UG,	US.	UZ.	VN,	YU,	ZA,	ZM.	ZW							
		RW:	GH,	GM,	KE.	LS.	MW.	MZ.	SD.	SL.	SZ.	tz,	UG.	ZM.	ZW.	AT.	BE.	CH.
												İT,						
												GW,						
	CA	2446										2002-						
		EP 1397364																
												IT.						
												TR		,	,	,	,	,
	BR	2002														2	0020	513
	CN	1511	157			A		2004	0707		CN :	2002 - 2002 -	B105	O.B.		- 2	0020	513
	JP	2004	5354	04		T2		2004	1125		JP :	1002-	5915	06		- 2	0020	513
												2002-						
												1003-						
												1003-						
												1003 -					0031	
e t c		r app										1001-						
•••					• •									·		•		
											NO 2	2002-	US11	8 R 4		w 2	0020	513
																-		

OTHER SOURCE(S): MARPAT 138:4598

L9 ANSWER 2 OF 2 CA COPYRIGHT 2006 ACS on STN (Continued) L9 ANSWER 2 OF 2 CA COPYRIGHT 2006 ACS on STN (Continued)

$$(\mathbb{R}^3)_p \xrightarrow{\mathbb{R}^1}_{\mathbb{R}^2} \mathbb{R}^2$$

Title compds. I [R1 = Ph, pyridine, pyridine-N-oxide, quinoline, naphthyridine, etc.; R2 = quinoline, quinoline-N-oxide, naphthalene, pyridine, pyridine-N-oxide, quinazoline, etc.; p = 1-8; R1 = H, alkyl, alkylhydroxy, hydroxy, dialkylamino, etc.; X = C, O, S] were prepared

alkylhydroxy, hydroxy, dialkylamino, etc.; X = C, 0, S] were prepared for instance, 1-[[2-(6-Bromoquinolin-4-y1)-1-(pyridin-2-y1)-thylidene]smino]pyrrolidin-2-one (preparetion given) was treated with NaH in DMF at 80-85° for 18 h to afford II in 54% yield. Selected compds. of the invention had ICSO < 20.00 μM for the TGP-β type I receptor.

IT 476473-43-1P, 4-(2-(Pyridin-2-y1)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-y1]quinoline-6-carboxylic acid methyl ester RL: PAC (Pharmacological activity); RCT (Reactant); SFN (Synthetic preparation); THU (Theraputic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of (hetero)aromatic substituted 5.6-dihydro-4H-pyrrolo[1,2-Dyrazoles as TGP-β signal transduction inhibitors)

RN 476478-43-CA
CN 6-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-y1]-, methyl ester (9CI) (CA INDEX NAME)

REFERENCE COUNT:

THERE ARE 13 CITED REFERENCES AVAILABLE FOR

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

```
10/531237
```

=> file marpat

=> s 16 full

L10 1 SEA SSS FUL L6

=> d ibib abs

GI

L10 ANSMER 1 OF 1 MARPAT COPYRIGHT 2006 ACS ON STN ACCESSION NUMBER: 138:4598 MARPAT TITLE: Preparation of substituted 5,6-dihydro-4H-pyrrolo[1,2-.2-b]pyrazoles as TGP-β signal transduction inhibitors Sawyer, Jason Scott; Beight, Douglas Made; Ciapetti, Paola; Decollo, Todd Vincent; Godfrey, Alexander Glenn; Goodson, Theodore, Jr.; Herron, David Kent; INVENTOR (S): Hong-yu; Liso, Junkai; Mcmillen, William Thomas; Miller, Shawn Christopher; Mort, Nicolas Anthony, Yingling, Jonathan Michael; Smith, Edward C. R. Eli Lilly and Company, USA; et al. PCT Int. Appl., 305 pp. CODEN: PIXXD2
Patent
English 1 PATENT ASSIGNEE(S): SOURCE: DOCUMENT TYPE: LANGUAGE: PAMILY ACC. NUM. COUNT: PATENT INFORMATION: PATENT NO. KIND DATE

WO 2002094833 A1 20021128 M0 2002-US11884 20020513

M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EE, PI, GB, GB, GH, LS, LT, LU, LV, MA, ND, MG, MK, MN, MM, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZM

RN: GH, GM, KE, LS, MM, MZ, SD, SI, SZ, TZ, UG, ZM, ZM, CM, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CT, CM, GA, GM, GQ, GW, HL, MR, NE, SN, TD, TG

CA 2446820 AA 20021128

EP 1397364 A1 20040317

R: AT, BE, CH, DE, DK, ES, FR, GB, GB, GE, IE, IT, LU, MC, NL, PT, SE, TR, BR 200209939 A 20040310

ER ST, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, KE, MC, PT, DE 2003008546 A2 20041025

NC 2003006564 A1 20041025

NC 2003006566 A 20051121

VIS 2004106604 A1 20040603 US 2001-295146 200310514

NC 2003005133 A 20031121

PRIORITY APPLN. INFO::

WO 2002-US11884 20020513

MO 2002-US11884 20020513

GI PATENT NO. KIND APPLICATION NO. DATE

Db1 Pat 10/477/1/

110 ANSWER 1 OF 1 MARPAT COPYRIGHT 2006 ACS on STN (Continued)

$$(R^3)_p \xrightarrow{X}_{N}^{N}_{N}$$

Title compds. I [R1 = Ph, pyridine, pyridine-N-oxide, quinoline, naphthyridine, etc.; R2 = quinoline, quinoline-N-oxide, naphthalene, pyridine, pyridine-N-oxide, quinazoline, etc.; p = 1-6; R2 = H, alkylalkylhydroxy, hydroxy, dialkylamino, etc.; X = C, O, S] were prepared Por instance, 1-[(2-(6-Bromoquinolin-4-y1)-1-(pyridin-2-y1)ethylidene] minoline, etc.; x = 0 = 1-0; R3 = H, alky instance, 1-[(2-(6-Bromoquinolin-4-y1)-1-(pyridin-2-y1)ethylidene] minolpyrrolidin-2-one (preparation given) was treated with NaH in DMP at 80-85° for 18 h to afford II in 54% yield. Selected compds. of the invention had ICSO < 20.00 µM for the TQP-β type I receptor.

REPERRICE COUNT: 13 THERE ARE 13 CITED REPERRICE THIS

13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR

RECORD. ALL CITATIONS AVAILABLE IN THE RE

page

### => d his

(FILE 'HOME' ENTERED AT 14:20:55 ON 08 MAR 2006)

FILE 'REGISTRY' ENTERED AT 14:21:00 ON 08 MAR 2006

L1 STRUCTURE UPLOADED

L2 0 S L1 SAM

L3 1 S L1 FULL

FILE 'CA' ENTERED AT 14:21:24 ON 08 MAR 2006

L4 1 S L3

FILE 'MARPAT' ENTERED AT 14:21:40 ON 08 MAR 2006

L5 1 S L1 FULL

FILE 'REGISTRY' ENTERED AT 14:22:01 ON 08 MAR 2006

L6 STRUCTURE UPLOADED

L7 0 S L6 SAM

L8 14 S L6 FULL

FILE 'CA' ENTERED AT 14:23:10 ON 08 MAR 2006

L9 2 S L8

FILE 'MARPAT' ENTERED AT 14:23:53 ON 08 MAR 2006

L10 1 S L6 FULL

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 14:24:46 ON 08 MAR 2006